-
Sector Analysis
Systemic Lupus Erythematosus and Lupus Nephritis: Epidemiology Forecast to 2034
Systemic lupus erythematosus (SLE) is the most common form of lupus. It is an autoimmune disease in which the body’s immune system mistakenly attacks its own healthy cells and organs, leading to inflammation and damage (Centers for Disease Control and Prevention, 2024). SLE is a chronic disease that can affect the skin, joints, blood, and organs such as the kidneys, lungs, and heart. There is currently no cure for SLE, but it can be treated. LN is one of the...
-
Sector Analysis
Age-Related Macular Degeneration Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
The table below presents the key metrics for age-related macular degeneration (AMD) in the seven major pharmaceutical markets (7MM) covered in this report—the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan—during the forecast period from 2024–34. In 2024, GlobalData estimated the total AMD market to be valued at $7.8 billion across the 7MM, with the US accounting for 67.2% of the market. The five major European markets (5EU) (France, Germany, Italy, Spain, and UK) accounted for 28.9%...
-
Sector Analysis
Age-Related Macular Degeneration: 68-Market Analysis and Sales Forecast tp 2034
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Age-Related Macular Degeneration (AMD) market. Across the 68 markets, sales in the AMD market were $8.9 billion in 2024, growing to $24.1 billion in 2034. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 87.0% and 85.2% in 68-market sales in 2024 and 2034, respectively.
-
Sector Analysis
Evaluating the Trump Administration’s New MFN Medicaid GENEROUS Model
Since the US president Donald Trump issued the Most Favored Nation (MFN) executive order, several pharmaceutical companies have agreed to comply with MFN pricing and more are expected to fall in line in the future. The Trump administration also recently revealed a new program for Medicaid, dubbed the GENErating cost Reductions fOr U.S. Medicaid (GENEROUS) model, where State Medicaid programs will be able to purchase drugs at MFN prices. The GENEROUS model revealed details on how international reference pricing (IRP)...
-
Sector Analysis
Resistant Hypertension: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2034
Understand the Future of the Resistant Hypertension Market The resistant hypertension (RH) therapeutics market is entering a new phase of growth as unmet medical needs, evolving treatment strategies, and pipeline innovation reshape the competitive landscape. This report provides a detailed analysis of the RH market across the 7MM (US, 5EU, and Japan), supported by an Excel-based forecast model through 2034. The report highlights a projected increase in diagnosed prevalent cases of resistant hypertension across the forecast period, alongside growing demand...
-
Thematic Analysis
FDI Trends in LATAM (2025)
Foreign Direct Investment (FDI) in the Latin American (LATAM) region is projected to increase in 2025, sculpted by commodity demand, competing US-Chinese investments, and expanded bilateral trade agreements conductive of FDI inflows. According to GlobalData’s FDI database, opened Greenfield FDI projects are projected to increase by ~1.8% in 2025, preceding consecutive years of growth in 2022, 2023 and 2024. Bucking the global trend, Foreign Direct Investment (FDI) in the Latin American (LATAM) region is projected to increase in 2025, sculpted...
-
Sector Analysis
Idiopathic Pulmonary Fibrosis (IPF) Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the 7 major markets and provides an Excel-based forecast model for the Idiopathic Pulmonary Fibrosis (IPF) market through 2034. GlobalData estimated that drug sales for IPF in 2024 were approximately $2.7 billion across the 7MM, with the market size anticipated to grow to approximately $5.8 billion by 2034, at a compound annual growth rate (CAGR) of 7.7%. Major drivers of growth during the forecast period include the launches of several pipeline agents, most notably Jascayd (nerandomilast), Tyvaso...
-
Sector Analysis
Cell and Gene Therapies in Respiratory Disorders: Therapeutic Analysis, Treatment Options, Regulations, Sales Forecast and Future Market Assessment
The cell and gene therapies (CGTs) landscape for respiratory diseases is currently in the early stages of development, with no marketed CGTs to date.
-
Sector Analysis
Diabetic Macular Edema (DME): Epidemiology Forecast to 2034
Diabetic macular edema (DME) is a vision-threatening complication of diabetes that is a major cause of vision impairment in diabetic individuals and is characterized by fluid accumulation in the macula due to a breakdown of the blood retinal barrier (BRB) (Cheema and Cheema, 2024). DME manifests as retinal thickening caused by the accumulation of intraretinal fluid, primarily in the inner and outer plexiform layers. It can occur due to hyperpermeability of the retinal vasculature. DME can occur with any level...
-
Sector Analysis
Insomnia: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2032
Understand the Future of the Insomnia Therapeutics Market The insomnia therapeutics market continues to evolve as treatment innovation, unmet patient needs, and changing prescribing patterns reshape the competitive landscape. This report provides a comprehensive analysis of the insomnia market across the 7MM, supported by an Excel-based forecast model covering the period from 2022 to 2032. Z-drugs remain the most common first-line treatment across the US and 5EU markets, while the current pipeline remains limited but diverse, featuring products with varying...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.